Showing results (1-10 of 159) with videos related to
Sort By:
Pageof 16
Seminars in Cutaneous Medicine and Surgery|July 1, 2014
New and emerging therapies in psoriasisCraig L Leonardi, Kenneth B GordonJournal of the American Academy of Dermatology|July 8, 2010
Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasisAlan Menter, Kenneth B Gordon, Craig L Leonardi, et al.Seminars in Cutaneous Medicine and Surgery|July 27, 2017
Highlights of Skin Disease Education Foundation's 41st Annual Hawaii Dermatology Seminar™Kenneth B Gordon, Craig L Leonardi, Daniel E Furst, et al.Journal of the American Academy of Dermatology|February 21, 2006
Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasisKim A Papp, Bruce Miller, Kenneth B Gordon, et al.The Journal of Dermatological Treatment|February 10, 2006
Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapyKenneth B Gordon, Alice B Gottlieb, Craig L Leonardi, et al.Journal of Drugs in Dermatology : JDD|December 31, 2004
Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasisAlice B Gottlieb, Kenneth B Gordon, Mark G Lebwohl, et al.Seminars in Cutaneous Medicine and Surgery|July 18, 2018
Highlights of Skin Disease Education Foundations 42nd Annual Hawaii Dermatology SeminarHilary E Baldwin, Linda F Stein Gold, Kenneth B Gordon, et al.Journal of the American Academy of Dermatology|September 23, 2014
A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasisKenneth B Gordon, Craig L Leonardi, Mark Lebwohl, et al.Dermatologic Clinics|September 29, 2004
Current concepts and review of efalizumab in the treatment of psoriasisCraig L LeonardiSeminars in Cutaneous Medicine and Surgery|June 1, 2018
Small Molecules for PsoriasisCraig L LeonardiPageof 16